Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma

Abstract

The 2015 World Health Organization (WHO) lung adenocarcinoma classification divides tumours into categories of indolent pre-invasive, minimally invasive and predominantly lepidic and, by examining predominant patterns of invasion, allows for further stratification into intermediate and highgrade tumours. The impact of the 2015 classification on prognosis was reviewed by a PubMed search for search terms "adenocarcinoma", "lung pathology" and "prognosis" and relevant publications reviewed. These were sorted for data on stage and survival as impacted by histological classification, and survival studies were separated into all stage versus stage 1 studies. Predictive aspects of histological classification were also examined, but molecular correlates were not. The separation of adenocarcinoma in situ and minimally invasive adenocarcinoma from invasive subtypes as distinct prognostic entities and the prognostic significance, for disease specific and overall survival for low-and high-grade categories, are discussed. The impact on stage at presentation including risk of node metastasis by histology is examined, as well as histology in relation to recurrence after surgery. Early data with regard to the value of predominant histology in the prediction of chemotherapy response will also be explored. @ERSpublications Lepidic lung ADC often early stage and indolent; solid and micropapillary tumours often metastatic and recurrent http://ow.ly/DCiT305xExK

Extracellular matrix alterations in low‐grade lung adenocarcinoma compared with normal lung tissue by imaging mass spectrometry

“…The major reason for low survival rate is attributed to highly variable symptoms and signs depending on where the tumor forms in the lung. It is estimated that around 70% of all patients diagnosed with LUAD present with advanced lung cancer . Lung cancer screening in high‐risk adults age 55 to 80 years has been shown to reduce 20% lung cancer–related mortality .…”

MiR‐21 improves invasion and migration of drug‐resistant lung adenocarcinoma cancer cell and transformation of EMT through targeting HBP1

“…Great progress has been made in early diagnosis, surgical techniques, and targeted therapy, whereas the prognosis for patients with NSCLC remains poor with 15% of 5‐year survival rate . The classification of lung adenocarcinoma has been revised to incorporate important new elements by the World Health Organization (WHO), which has prognostic significance and might help predict therapeutic approaches . The poor outcome is mainly accounted for by chemoresistance, an inevitable occurrence in lung adenocarcinoma .…”

Long non‑coding RNA DANCR promotes HMGA2‑mediated invasion in lung adenocarcinoma cells

“…It is common to for distant metastasis to occur in patients with LAD, including bone metastasis, cutaneous metastasis, thyroid metastasis and brain metastasis (2)(3)(4)(5). Despite comprehensive treatment approaches, including chemotherapy, radiotherapy, surgical resection and molecular targeted therapy, the 5-year survival rate of LAD remains unsatisfactory (6,7). Therefore, understanding the molecular mechanisms and pathways of LAD metastasis is important to increase the treatment efficacy and improve the prognosis of patients with LAD.…”